Indication

Progressive pulmonary fibrosis

Progressive pulmonary fibrosis is a clinical phenotype characterized by the relentless worsening of fibrotic lung disease in patients with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis. Read more about Progressive pulmonary fibrosis

13 drugs 12 manufacturers

Advertisement

Drugs that treat it

Common Progressive pulmonary fibrosis therapies.

Showing 1–9 of 13 drugs

OFEV (nintedanib esylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
Boehringer Ingelheim

JASCAYD (nerandomilast)

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·IDIOPATHIC PULMONARY FIBROSIS·+1
Boehringer Ingelheim

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
DR.REDDY'S LAB

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
APOTEX CORP

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
CIPLA USA, INC.

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
EDENBRIDGE/DEXC

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
SANDOZ

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
GSMS, INC.

NINTEDANIB ESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE·+2
EXELAN PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Progressive pulmonary fibrosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Progressive pulmonary fibrosis.

Progressive pulmonary fibrosis is a clinical phenotype characterized by the relentless worsening of fibrotic lung disease in patients with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis.

It affects the respiratory system across diverse populations, occurring as a complication of varied conditions including autoimmune or connective tissue diseases, fibrotic hypersensitivity pneumonitis, idiopathic nonspecific interstitial pneumonia, and unclassifiable ILDs.

Pathophysiologically, it features self-sustaining alveolar architecture destruction, fibroproliferation, and excessive extracellular matrix deposition.

Clinically, it is defined by the occurrence of at least two of three criteria within the preceding year without an alternative explanation: worsening respiratory symptoms, physiological disease progression (such as absolute decline in forced vital capacity or gas transfer), and radiologic evidence of disease progression on high-resolution computed tomography.

Personalize your experience

Follow Progressive pulmonary fibrosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it